Matthew Howell
Research Subjects
Matthew Howell has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
A. Chittalia
Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
2 shared publicationsA. Lewis
Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
2 shared publications- Crispin J. Miller
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
2 shared publications D. Nonaka
2 shared publications- Fiona Blackhall
The Christie NHS Foundation Trust 3 , Manchester, United Kingdom
2 shared publications G. Papaxoinis
2 shared publications
Latest Publications
- Top Cited Papers
- 22 April 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (5) , 738-743
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Sequencing of circulating tumor DNA from cancer patients is a cost-efficient approach with turnaround time compatible with clinical practice to inform treatment decision-making in a phase 1 trial setting
- 22 April 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (5) , 738-743
Top Cited PapersUtility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Sequencing of circulating tumor DNA from cancer patients is a cost-efficient approach with turnaround time compatible with clinical practice to inform treatment decision-making in a phase 1 trial setting
- Open Access
- 4 October 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 14830
Mutation pattern analysis reveals polygenic mini-drivers associated with relapse after surgery in lung adenocarcinoma
The genomic lesions found in malignant tumours exhibit a striking degree of heterogeneity. Many tumours lack a known driver mutation, and their genetic basis is unclear. By mapping the somatic mutations identified in primary lung adenocarcinomas onto an independent coexpression network derived from normal tissue, we identify a critical gene network enriched for metastasis-associated genes. While individual genes within this module were rarely mutated, a significant accumulation of mutations within this geneset was predictive of relapse in lung cancer patients that have undergone surgery. Since it is the density of mutations within this module that is informative, rather than the status of any individual gene, these data are in keeping with a ‘mini-driver’ model of tumorigenesis in which multiple mutations, each with a weak effect, combine to form a polygenic driver with sufficient power to significantly alter cell behaviour and ultimately patient outcome. These polygenic mini-drivers therefore provide a means by which heterogeneous mutation patterns can generate the consistent hallmark changes in phenotype observed across tumours.
- 4 October 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 14830
Open AccessMutation pattern analysis reveals polygenic mini-drivers associated with relapse after surgery in lung adenocarcinoma
The genomic lesions found in malignant tumours exhibit a striking degree of heterogeneity. Many tumours lack a known driver mutation, and their genetic basis is unclear. By mapping the somatic mutations identified in primary lung adenocarcinomas onto an independent coexpression network derived from normal tissue, we identify a critical gene network enriched for metastasis-associated genes. While individual genes within this module were rarely mutated, a significant accumulation of mutations within this geneset was predictive of relapse in lung cancer patients that have undergone surgery. Since it is the density of mutations within this module that is informative, rather than the status of any individual gene, these data are in keeping with a ‘mini-driver’ model of tumorigenesis in which multiple mutations, each with a weak effect, combine to form a polygenic driver with sufficient power to significantly alter cell behaviour and ultimately patient outcome. These polygenic mini-drivers therefore provide a means by which heterogeneous mutation patterns can generate the consistent hallmark changes in phenotype observed across tumours.
- 17 April 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 11 (526)
Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases
A kinase domain–focused functional genomic screen reveals loss-of-function mutations in a JNK pathway kinase in gastric cancer.
- 17 April 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 11 (526)
Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases
A kinase domain–focused functional genomic screen reveals loss-of-function mutations in a JNK pathway kinase in gastric cancer.
- 15 November 2017
- Published by BMJ
- Vol. 72 (Suppl 3) , A159-A160
P141 Pulmonary function test physiology and progression in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (dipnech)
Introduction Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare condition characterised by a generalised proliferation of pulmonary neuroendocrine cells within the respiratory epithelium. Current literature is limited, in particular little is known of its affects on pulmonary function both at the time of diagnosis and prospectively, though it is recognised to cause small airway obstruction. Objective The aim of this study was to characterise pulmonary function, both at baseline and to also define the change in pulmonary function over time in patients with DIPNECH. Methods Retrospective analysis of pulmonary function data for patients with a histological diagnosis of DIPNECH was performed. At baseline, pulmonary function was characterised as either obstructive, small airways obstruction, restrictive, mixed (obstructive and restrictive) or normal. Baseline gas transfer (DLCO) and lung volume data was also described. FEV1 was used as the main measure of pulmonary function, and simple linear regressions were created for patients with longitudinal data. This then allowed basic statistical analysis of the change in FEV1 compared to the predicted change. Results 17 patients (82% female), with a mean age of 59, were included. All had pulmonary function data at baseline and 9 (53%) had prospective data. Baseline pulmonary function was predominantly obstructive in nature with 6 (35%) having classical obstruction, and 7 (41%) small airways obstruction alone with a normal FEV1/FVC ratio, the remaining 4 having either normal (n=3, 23%) or mixed (n=1, 6%) physiology. The mean FEV1 at baseline was 81.6%, and a statistically significant difference was present between mean measured and predicted FEV1 values for the cohort (p=0.02). Mean DLCO (n=13) was mildly decreased at 84.6% predicted however corrected to normal with volume. Lung volume data (n=8) where available was normal, except in two patients (12%) who had significantly increased residual volume. Patients with longitudinal data (n=9, 53%) predominantly showed a stable pattern of obstruction with minimal decline. Two patients (12%) did have a significantly increased decline compared to predicted values. Conclusion Patients with DIPNECH typically have a stable degree of fixed obstruction, however exceptions to this will be seen in patients with a more progressive disease.
- 15 November 2017
- Published by BMJ
- Vol. 72 (Suppl 3) , A159-A160
P141 Pulmonary function test physiology and progression in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (dipnech)
Introduction Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare condition characterised by a generalised proliferation of pulmonary neuroendocrine cells within the respiratory epithelium. Current literature is limited, in particular little is known of its affects on pulmonary function both at the time of diagnosis and prospectively, though it is recognised to cause small airway obstruction. Objective The aim of this study was to characterise pulmonary function, both at baseline and to also define the change in pulmonary function over time in patients with DIPNECH. Methods Retrospective analysis of pulmonary function data for patients with a histological diagnosis of DIPNECH was performed. At baseline, pulmonary function was characterised as either obstructive, small airways obstruction, restrictive, mixed (obstructive and restrictive) or normal. Baseline gas transfer (DLCO) and lung volume data was also described. FEV1 was used as the main measure of pulmonary function, and simple linear regressions were created for patients with longitudinal data. This then allowed basic statistical analysis of the change in FEV1 compared to the predicted change. Results 17 patients (82% female), with a mean age of 59, were included. All had pulmonary function data at baseline and 9 (53%) had prospective data. Baseline pulmonary function was predominantly obstructive in nature with 6 (35%) having classical obstruction, and 7 (41%) small airways obstruction alone with a normal FEV1/FVC ratio, the remaining 4 having either normal (n=3, 23%) or mixed (n=1, 6%) physiology. The mean FEV1 at baseline was 81.6%, and a statistically significant difference was present between mean measured and predicted FEV1 values for the cohort (p=0.02). Mean DLCO (n=13) was mildly decreased at 84.6% predicted however corrected to normal with volume. Lung volume data (n=8) where available was normal, except in two patients (12%) who had significantly increased residual volume. Patients with longitudinal data (n=9, 53%) predominantly showed a stable pattern of obstruction with minimal decline. Two patients (12%) did have a significantly increased decline compared to predicted values. Conclusion Patients with DIPNECH typically have a stable degree of fixed obstruction, however exceptions to this will be seen in patients with a more progressive disease.
- 15 November 2016
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 19 (5) , 579-586
Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours
Pulmonary carcinoid (PC) tumours are classified as either typical (TC) or atypical (AC) according to mitotic index (MI) and presence of necrosis. The aim of this study was to analyse the diagnostic and prognostic values of the Ki-67 index in PC.
- 15 November 2016
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 19 (5) , 579-586
Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours
Pulmonary carcinoid (PC) tumours are classified as either typical (TC) or atypical (AC) according to mitotic index (MI) and presence of necrosis. The aim of this study was to analyse the diagnostic and prognostic values of the Ki-67 index in PC.
- 22 July 2016
- Published by Wiley in British Journal of Haematology
- Vol. 179 (5) , 841-843
Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin
- 22 July 2016
- Published by Wiley in British Journal of Haematology
- Vol. 179 (5) , 841-843
Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin
- 1 January 2016
- Published by Elsevier in Lung Cancer
- Vol. 91, 75-76
Outcomes of octogenarian (≥80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie Hospital
- 1 January 2016
- Published by Elsevier in Lung Cancer
- Vol. 91, 75-76
Outcomes of octogenarian (≥80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie Hospital
- 1 May 2015
- Published by Elsevier in Lung Cancer
- Vol. 88 (2) , 117-123
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
- 1 May 2015
- Published by Elsevier in Lung Cancer
- Vol. 88 (2) , 117-123
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
- 1 April 2015
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 29 (2) , 333-343
The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma
- 1 April 2015
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 29 (2) , 333-343
The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma